Evidence map›Paper›PMID 22183842›Full record

ArticleSexually transmitted diseases2012

Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials.

Carmen Radecki Breitkopf, Melissa Loza, Kathleen Vincent, Thomas Moench, Lawrence R Stanberry, Susan L Rosenthal

Open access · greenAbstract read
In one paragraph

Article in Sexually transmitted diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Perceptions of reimbursement for clinical trial participation.Journal of empirical research on human research ethics : JERHRE · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Carmen Radecki BreitkopfDepartment of Health Sciences Research, Division of Health Care Policy & Research, Mayo Clinic, Rochester, MN 55905, USA. radeckibreitkopf.carmen@mayo.edu
Melissa Loza
Kathleen Vincent
Thomas Moench
Lawrence R Stanberry
Susan L Rosenthal
Columbia University · USThe University of Texas Medical Branch at Galveston · USMayo Clinic · USReProtect (United States) · US

Funding

UTMB CLINICAL AND TRANSLATIONAL SCIENCE AWARD: NASA BED REST STUDIESUL1RR029876 · NCRR · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2009 to 2011
$17.7M
Supplement to grant: Development of Dendrimer and Combination MicrobicidesU19AI060598 · NIAID · STARPHARMA, LTD · PI PAULL, JEREMY · 2004 to 2009
$6.9M
NCRR NIH HHS 1UL1RR029876-01NCRR NIH HHS UL1 RR029876NIAID NIH HHS U19 AI060598
6 · The paper itself

Abstract

backgroundDeveloping effective and safe microbicides requires study procedures (e.g., technology used, abstinence requirements, and product use) that are acceptable to participants.

methodsThirty women completed 4 study visits including pelvic examination, colposcopy, optical coherence tomography (OCT), and semistructured, qualitative interviews. Additional requirements included abstinence (for approximately 16 days) and twice daily vaginal product use (for 5.5 days). Interviews were audio-recorded, transcribed, and analyzed using framework analysis. Themes addressing OCT experiences, acceptability of abstinence, and vaginal product use were examined.

resultsOCT was viewed favorably as an imaging technology. Some women reported feeling the fiber-optic probe "poking" them and more than one-third spontaneously reported feeling pressure or pinching upon rotation of the speculum in connection with the OCT evaluation. Compliance with vaginal gel use was high, but for many women assigned to use a product containing nonoxynol-9 (vs. placebo), the postproduct use examination was more uncomfortable, relative to the initial examination or 1 week following product discontinuation. Nearly all women experienced product leakage; acceptability of leakage varied. Two women were not abstinent and several more found abstinence challenging. Some women involved their partner in decision making regarding trial enrollment. Strategies to remain abstinent included participating when the partner was away, avoiding early intimacy, and engaging in alternative sexual activities.

conclusionsQualitative interviews in early-phase studies provide insights and capture information that would be missed by behavioral inference alone. Understanding participant's experiences is important in order to provide anticipatory guidance and plan future microbicide studies that facilitate adherence with trial requirements.

Indexed as

Administration, IntravaginalAdultAnti-Infective AgentsFemaleHumansInterviews as TopicMiddle AgedNonoxynolPatient CompliancePatient SatisfactionSafetySexual AbstinenceSexual BehaviorSurface-Active AgentsTomography, Optical CoherenceVaginal Creams, Foams, and JelliesAnti-Infective AgentsNonoxynolSurface-Active AgentsVaginal Creams, Foams, and Jellies

Identifiers

PMID22183842
PMCPMC3243962
OpenAlexW2024496492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.